Methods of screening and identifying TGF-beta antagonists, such as activin-A antagonist. These antagonists may be useful as therapeutics for disease treatment.
Reference# CLFR035
Patent# US7575751
Hide Details

Immunoreactive gp47 and gp36 proteins in Ehrlichia chaffeensis and E. canis are provided. These proteins may be used for diagnosis of Ehrlichiosis in humans and/or dogs. The proteins may also be included in vaccine compositions against Ehrlichia infection.
Reference# CLFR256
Application# US11/917390
Hide Details

Clayton researchers have developed the following transgenic mice that are available for non-exclusive licensing: CRFR1 knock-out CRFR2 knock-out Urocortin knock-out ACC2 knock-out
Hide Details

Methods for inhibiting NF-kB activity by targeted delivery of a polypeptide inhibitor of NF-kB (IkB). Methods of the invention may be used to treat diseases such as infections and cell proliferative disorders such as cancer and autoimmune disease. Methods for sensitizing cells to apoptosis and cytotoxic therapies such as chemotherapy and radiation therapy are also described.
Reference# CLFR269
Application# US 11/679630
Hide Details

Methods for increasing insulin sensitivity in an individual by reducing corticotropin releasing factor receptor-2 (CRFR-2) signaling. Methods of decreasing insulin secretion in the pancreas are also described. These methods are of particular relevance in subjects who have become insulin resistant such as those with type 2 diabetes or metabolic syndrome.
Reference# CLFR259
Application# US 11/668047
Patent# US 7815905
Hide Details

Methods for inhibiting NF-kB by the intracellular delivery of a polypeptide that blocks NF-kB phosphorylation and activation. For example, protein sequences that mediate cell internalization are fused to amino acid sequences from the p65 NF-kB subunit. NF-kB inhibition may be used for methods in treating, for example, cell proliferative diseases such as cancer and autoimmune disease.
Reference# CLFR241
Application# US 10/981082
Patent# US7368430
Hide Details

Methods and compositions for blocking the activity of Cripto, a developmental oncoprotein. Such methods may enhance the anti-proliferative effects of activin and TGF-beta. Polypeptides comprising a mutant activin receptor-like kinase ALK-4 extracellular domain are also provided and may be used to inhibit cell proliferation.
Reference# CLFR240
Application# 10/940431
Patent# EP1670511 US 7820620
Hide Details

Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as adrenocorticotropic hormone (ACTH). Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance, methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described.
Reference# CLFR273
Application# US 12/897591
Patent# US 7,807,143
Hide Details

Cleavage site for the protease furin is inserted between domains of a membrane glycoprotein, such as a viral glycoprotein. When expressed in cells with furin activity protein is separated into individual membrane-free domain that retains its native conformation. Such membrane-free protein may be used for structural analysis or subunit vaccines. In some cases, viruses with the inserted furin cleavage site many be grown in cells lacking furin activity and used as live attenuated vaccines.
Reference# CLFR236
Patent# US7521209, US7223390
Hide Details

Methods and composition for the screening and isolation of aglycosylated antibody Fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated Fc domains that bind to Fc receptors or preferentially bind to particular Fc receptors are described. Furthermore, the invention provides aglycosylated Fc domains that bind to Fc receptors with high affinity. Enhanced methods and media for prokaryotic based interaction screening are also provided.
Reference# CLFR292
Application# US12/112971
Hide Details

Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules.
Reference# CLFR278
Application# US11/948672
Patent# US11/948672
Hide Details

Methods for treating or preventing tauopathies by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer’s disease by administration of CRF-R1 selective antagonist are provided.
Reference# CLFR285
Application# US12/663805
Hide Details

A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in which the survival is enhanced by exposure to the pyridine analog. In further embodiments, a method of preparing neuronal cells is provided in which pluripotent or neural stem cells exposed to the pyridine analog are then incubated without the pyridine analog, resulting in differentiation into neurons, astrocytes and oligodendrocytes.
Reference# CLFR286
Application# US12/747116
Hide Details

miRNAs are provided which affect threshold expression of critical asthma related genes.
Reference# CLFR342
Application# PCT/US2010/034119
Hide Details

Cripto is a recognized oncogene that plays a key role in cancer. Antagonists of Cripto, such as Alk4-L75A and Cripto7Grp78 inhibitors are excellent therapeutic candidates to treat solid tumors.
Hide Details

Method of treating individuals with sever burns by administration of beta-adrenergic receptor antagonists, such as propranolol.
Reference# CLFR218
Patent# US7098248
Hide Details

Methods for predicting and inhibiting tumor angiogenesis related to nucleoside diphosphate kinase-B activity. Inhibitors of nucleoside diphosphate kinase-B such as ellagic acid, epigallocatechin gallate, and epicatechin gallate may be used to block tumor angiogenesis.
Reference# CLFR219
Application# US 10/331375
Patent# US7678549
Hide Details

Immunoreactive thio-disulfide oxidoreductases, or disulfide bond formation (Dsb) proteins from Ehrlichia chaffeensis and Ehrlichia canis. Detection these proteins may be used to determine whether an individual or animal is infected E. chaffeensis and/or E. canis.
Reference# CLFR220
Patent# US7432081, US7824692
Hide Details

Methods of cancer treatment using a combination of a cancer chemotherapeutic agent and an inhibitor of nuclear factor NF-kappa B activation, such as curcumin. For example, breast tumor metastasis can be inhibited with a combination of curcumin and taxol.
Reference# CLFR223
Application# US 10/422292
Patent# US7105576
Hide Details

Methods and compositions for the intracellular transport of liposomal filaggrin for treatment of skin disease are provided.
Reference# CLFR333
Application# PCT/US2010/057592
Hide Details

Antibodies with an engineered Fc domain to specifically enhance therapeutic effector function.
Application# US12/112971 and US12/827386
Hide Details

Methods for treating multiple myeloma with inhibitor of NF-kappa B activation, such as curcumin. These treatment methods may also be used in combination with other agents, such as vincristine.
Reference# CLFR234
Application# US 10/602303
Patent# US7196105
Hide Details

Sequences encoding two immunoreactive glycoproteins from Ehrlichia canis and Ehrlichia chaffeensis. These two glycoproteins are species-specific and immunoreactive and may be used for subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.
Reference# CLFR235
Patent# US7204992, US7754224, EP1581638, KR10-1063177, MX257637, CN200380108238.6, CN200810087960.0
Hide Details

Methods of inhibiting osteoclast development that may be induced by the receptor for activation of nuclear factor kappa B ligand (RANKL). Methods can involve contacting an osteoclast, or a precursor of an osteoclast, with a compound such as diferuloylmethane, guggulsterone, 1'-Acetoxychavicol or related analogues.
Reference# CLFR243
Application# US 10/925608
Patent# US7462646
Hide Details

An immunoreactive ferric binding protein (Fbp) (38-kDa) protein of Ehrlichia canis. This protein may be used in vaccine compositions to immunize animals against E. canis.
Reference# CLFR244
Application# 11/066648
Patent# US7722880
Hide Details